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Abstract
Introduction: Current studies indicate that triple negative breast cancer (TNBC), an aggressive breast cancer subtype, is
associated with poor prognosis and an early pattern of metastasis. Emerging evidence suggests that MUC4 mucin is
associated with metastasis of various cancers, including breast cancer. However, the functional role of MUC4 remains
unclear in breast cancers, especially in TNBCs.
Method: In the present study, we investigated the functional and mechanistic roles of MUC4 in potentiating pathogenic
signals including EGFR family proteins to promote TNBC aggressiveness using in vitro and in vivo studies. Further, we
studied the expression of MUC4 in invasive TNBC tissue and normal breast tissue by immunostaining.
Results: MUC4 promotes proliferation, anchorage-dependent and-independent growth of TNBC cells, augments TNBC cell
migratory and invasive potential in vitro, and enhances tumorigenicity and metastasis in vivo. In addition, our studies
demonstrated that MUC4 up-regulates the EGFR family of proteins, and augments downstream Erk1/2, PKC-c, and FAK
mediated oncogenic signaling. Moreover, our studies also showed that knockdown of MUC4 in TNBC cells induced
molecular changes suggestive of mesenchymal to epithelial transition. We also demonstrated in this study, for the first time,
that knockdown of MUC4 was associated with reduced expression of EGFR and ErbB3 (EGFR family proteins) in TNBC cells,
suggesting that MUC4 uses an alternative to ErbB2 mechanism to promote aggressiveness. We further demonstrate that
MUC4 is differentially over-expressed in invasive TNBC tissues compared to normal breast tissue.
Conclusions: MUC4 mucin expression is associated with TNBC pathobiology, and its knockdown reduced aggressiveness
in vitro, and tumorigenesis and metastasis in vivo. Overall, our findings suggest that MUC4 mucin promotes invasive
activities of TNBC cells by altering the expression of EGFR, ErbB2, and ErbB3 molecules and their downstream signaling.
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urgent need to investigate the underlying molecular mechanisms
responsible for the aggressive nature of TNBC, and to develop
targeted approaches for treatment of invasive TNBCs.
Epithelial cells produce mucins to lubricate and protect
themselves from extrinsic physical and biological assaults [6].
However, aberrant expression of mucins has been reported to
promote cancer development, and affects cellular growth, transformation, and invasion [7]. Aberrantly over-expressed membrane-tethered mucins, including MUC1 [8] and MUC4 [6], play
diverse functional roles in several epithelial cancers, including
ovarian, pancreatic [9,10], and breast [11]. We have previously
demonstrated that MUC4 enhances tumorigenicity and metastasis

Introduction
Triple negative breast cancers (TNBCs) represent approximately 10–17% of all breast cancer incidents [1]. In comparison to the
luminal subtypes, TNBCs are associated with poor prognosis [2],
short survival, and high recurrence rates after adjuvant therapy
[3]. TNBCs are associated with increased risk for visceral [4] and
brain metastases, and also require more aggressive treatment.
Although several therapeutic options targeting EGFR, PARP1,
VEGF-a, Src, HDAC, and MEK are being investigated in clinical
trials [5], the overall prognosis of patients with TNBC remains
dismal owing to a lack of effective treatment. Thus, there is an
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in pancreatic [7,12] and ovarian [10] cancer. Furthermore our
studies have established that MUC4 is associated with drug
resistance in pancreatic cancer [13,14]. An earlier study reported
that there is a high incidence of MUC4 expression in breast cancer
[15], which is associated with metastatic disease [16]. However,
inadequate information is available regarding the functional role(s)
of MUC4 mucin in breast cancer especially in TNBC.
In the current study, we investigated the role of MUC4 in
TNBC by in vitro and in vivo functional studies, and by studying the
expression of MUC4 in TNBC tissue. MUC4 potentiated
oncogenic signals to promote proliferation, growth, motility, and
invasiveness of TNBC cells in vitro, and tumorigenicity and
metastasis in vivo. Furthermore, compared to normal breast tissues,
MUC4 expression was overexpressed in invasive TNBC tissues.
Thus, we propose that MUC4 mucin is a new potential target for
treatment of invasive and metastatic TNBCs.

well of the 6-well plates were counted for 7 days by a viable cell
counter (ViCell Coulter counter, Beckman Coulter, Inc., Brea,
CA). Population doubling times of control and MUC4 knockdown
cells were calculated from the number of cells growing in the log
phase (96–144 h) and using the formula: Td = 0.693t/ln (Nt/N0),
where t is time (in h), Nt is the cell number at time t, and N0 is the
cell number at initial time.

Colony Forming Assay
Colony forming assays were performed as described previously
[17]. Briefly, colony-forming efficiency was examined 14 days after
plating 250 cells/60 mm dish in quadruplicate, by staining with
crystal violet (Sigma, St. Louis, MO). Colonies of .50 mm in size
were counted using quantity One software (Bio-Rad, Richmond,
CA, USA). Results are an average of 3 independent experiments.

Assay for Anchorage Independent Growth in Soft Agar

Materials and Methods

Anchorage-independent growth assays were performed as
described previously [18]. Briefly, 2.5 6 104 cells of control and
MUC4 knockdown cells were plated in 6-well plates in 1.5 mL of
0.35% low melting agarose (Sigma) in a–MEM media on top of
a bottom layer of 0.5% agarose in a–MEM media. Plates were
incubated for 2 weeks. Phase-contrast images were obtained under
406 magnification, and colonies were counted and plotted.
Control and MUC4 knockdown cells were used for each
experiment in triplicate. At least two independent experiments
were performed.

Cell Culture
MDA-MB-231 (HTB-26), BT-20 (HTB-19), and MDA-MB468 (HTB-132) parental cell lines were a generous gift from Dr.
Vimla Band, University of Nebraska Medical Center, Omaha,
NE, USA. These cell lines are commercially available in American
Type Culture Collection (ATCC) and already published in many
research articles. A limited number of passages of ATCC
characterized cells was maintained, tested to be free of mycoplasma contamination, and cryopreserved. All experiments were
performed with cells at less than 20 passages after receipt. The aMEM media (Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin,
2 mM L-glutamine, 10 mM HEPES (pH 7.4), and 16NEAA was
used for maintaining MDA-MB-231 cells and also to maintain
sustained MUC4 expression. After stable transfection and clone
selection, control MDA-MB-231-SCR and MUC4 knockdown
MDA-MB-231-shMUC4 cells were maintained in complete aMEM media with the addition of 1–3 mg/ml puromycin.

Immunoblot Assays
Protein extraction and immunoblotting were performed using
standard procedures with control and MUC4 knockdown cells for
EGFR, ErbB2, ErbB3, ErbB4, b–catenin, cyclin D1, CK-18,
vimentin, vitronectin, ERK, FAK, and b-actin expression. 2%
SDS-agarose gel electrophoresis was performed for MUC4 using
25 mg protein samples under reducing conditions as described
previously [19]. ErbB2 (sc-52349), ErbB3 (sc-7390), ErbB4 (sc8050), cyclin D1(sc-718), vitronectin (sc-28929), FAK (sc-557), pFAK (sc-7383), HSC70 (sc-7298), Sprouty 2 (sc-30049) were
purchased from Santa Cruz Biotechnology, CA, US. Anti-CK-18
(K0199-21) was purchased from US Biological, MA, US);
antibodies against vimentin (V-2258), b-actin (A-2066) were
purchased from Sigma-aldrich, St. Louis, MO, US; Erk1/2
(9194); anti-p-Erk1/2 (9101) was purchased from Cell signaling,
MA, US; anti-PKCc (ab71558) was from Abcam, Cambridge,
MA, US; anti-Zonula occludens-1 (40–2300) from Invitrogen,
Carlsbad, CA. EGFR (ICI). Anti-MUC4 antibodies 8G7 and 2214
were generated and characterized in our laboratory [20]. bcatenin antibody was from kind gift Dr. Keith Johnson, UNMC,
NE.

Stable Silencing of MUC4 using a Plasmid Construct
(pSUPER-retro-puro-shMUC4)
The method of generating the shRNA construct for in vitro
stable knockdown of MUC4 has been described previously [7].
Briefly, phoenix packaging cells were transfected with the
pSUPER-retro-puro vector containing either the MUC4 shRNA
insert (pSUPER-retro-puro-shMUC4) or a scrambled sequence
(pSUPER-retro-puro-SCR) using FuGENE 6 (Invitrogen) following the manufacturer’s protocol. Media containing infectioncompetent retroviruses containing supernatant were collected 48 h
after transfection. Polybrene (4 mg/mL) was added with the
retroviruses to enhance the target cell infection efficiency. Cells
(MDA-MB-231) were plated in 100 mm dishes at 60% confluence
and infected with the retroviruses. Stable pooled populations of
MDA-MB-231-SCR (control) and MDA-MB-231-shMUC4
(MUC4 knockdown) cells were generated by selection using
puromycin, and levels of mRNA transcripts, expression of protein,
and the phenotype of cells were analyzed. The control and MUC4
knockdown cells were used for all functional studies.

Three-dimensional Morphogenesis Assay and Confocal
Imaging
The three-dimensional Matrigel assays were performed following the method described previously [21]. Approximately, 2.5 6
103 cells per well, as single cell suspensions, were plated onto an
eight-well chamber slides on top of a polymerized layer of 100%
growth factor reduced Matrigel (BD BioSciences, San Jose, CA,
US), with 0.4 mL assay media containing 2% Matrigel using the
overlay method [22]. Stable transfactants were cultured with
puromycin. The medium was changed after every 3 days for each
set. 3D structures formed by both control and MUC4 knockdown
cells were quantified. Acinar-like structures were defined as
regular, round structures that were clearly identified by bright

Growth Kinetic Studies
Growth kinetics and population doubling time of control and
MUC4 knockdown cells were determined as described previously
[12]. Briefly, for growth curves, control and MUC4 knockdown
cells were seeded at 16104 cells/well in 6-well-plate in triplicate.
Viable cells of control and MUC4 knockdown populations in each
PLOS ONE | www.plosone.org
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field microscopy at 206 magnification; protrusive structures were
defined as those exhibiting one or more multicellular outgrowths
clearly invading the surrounding Matrigel. This observation was
further confirmed by staining with junctional protein zonula
occludens-1 (ZO-1). Immunofluorescence microscopy was performed following a standard methodology as described previously
[21].

during mounting. After washing in PBS and then water, images
were captured and analyzed with a laser scanning confocal
microscopy (Zeiss LSM 510 META, Carl Zeiss Microscopy
GmbH, 07740 Jena, Germany).
For F-actin (filamentous actin) staining, phalloidin (fluorescent
phallotoxins from Invitrogen) was used as described in the
manufacturer’s protocol. Briefly, cells were grown onto sterile
18 mm glass coverslips and fixed with 3.7% formaldehyde and
permeabilized with 0.5% Triton X-100. Phalloidin at 1:40 in PBS
was used to stain F-actin for 1 h. DAPI staining was done during
mounting. Images were captured and analyzed with a laser
scanning confocal microscopy (Zeiss LSM 510 META).

Quantitative Real-time Polymerase Chain Reaction
Quantitative real-time PCR was performed using standard
procedures using a LightCycler 480 SYBR Green 1 Master
(Roche, Germany) with specific primers as described previously
[23]. The forward and reverse primers for MUC4, and b-actin
were custom synthesized from IDT technology (Integrated DNA
Technology, Coralville, IA, USA) and are listed in Table S2.

Cell Cycle Analysis
Cell cycle analysis was performed by flow cytometry using
standard procedures as described previously [17]. Briefly, cells
were serum starved for 48 hours and re-stimulated with serum for
24 hours. After serum re-stimulation, cells were harvested with
a PBS-based enzyme-free cell dissociation buffer (Invitrogen)
followed by HPBS washing. MDA-MB-231-SCR and MDA-MB231-shMUC4 cells were fixed for 1 hour in 70% ethanol, washed
36 with HPBS (pH 7.4), and resuspended in Telford reagent
composed of propidium iodide (50 mg/ml) supplemented with
EDTA (90 mM), Triton X-100 (0.1%), and RNase A (1 mg/ml).
DNA content was measured using a FACScan cytometer
(FACStar, Becton Dickinson, Franklin Lakes, NJ, USA). All
samples were analyzed in triplicate, and the data presented are the
average of the three independent experiments.

Immunohistochemistry
Immunohistochemical analysis of tumor microarrays and
sections, obtained from tumors generated by orthotopic implantation of control and MUC4 knockdown cells, was performed as
described previously [24]. Briefly, after baking at 56uC overnight,
the tissues were dewaxed in xylene twice for 5 min, followed by
rehydration through graded ethanol. Endogenous peroxidase
activity was quenched by incubating the slides with 3% hydrogen
peroxide in methanol for 30 min. Antigen retrieval was performed
in 0.01 M pre-heated citrate buffer (pH 6.0, 95uC) in a microwave
for 15 min. Non-specific reactivity with the antibody was blocked
by incubating the slides with horse serum (ImmPRESS Universal
Antibody Kit, Vector Labs, Burlingame, CA, USA) for 2 h
followed by the addition of the primary anti-MUC4 antibody
[1:200] (Mouse monoclonal antibody 2214; 1.66 mg/ml). After
overnight incubation at 4uC, the slides were washed with PBS and
incubated with universal secondary antibody (ImmPRESS Universal Antibody Kit, Vector Labs) for 30 min. Staining was
visualized by adding 3, 39-diaminobenzidine solution (DAB
Substrate Kit, Vector Labs). The slides were counterstained with
Gill’s hematoxylin (Vector Labs) and dehydrated in graded
ethanol and washed with xylene. The slides were mounted with
a few drops of permanent mounting medium (Permount, Fisher
Scientific, Pittsburgh, PA, USA). All slides were observed under
a Nikon light microscope and photographs of representative areas
taken with the Q-capture Micropublisher 5.0 camera (Leeds
Precision Instruments, Minneapolis, MN, USA) using the Qcapture suite software package (QImaging, Surrey, BC, Canada).
The intensity of MUC4 expression was graded on a scale of 0 to 3
(0: no staining; 1+: weakly positive; 2+: moderately positive; 3+:
strongly positive). The percentage of MUC4-positive cells was
quantified.

Wound Healing and Trans-well Migration Assay
The motility assay was performed as described previously [26].
Briefly, control and MUC4 knockdown cells (16105/well) were
seeded in 12-well plates. Cells were incubated in serum-free
medium for 32–48 h prior to generating the wound by scraping
with a plastic tip across the cell monolayer. Cells were incubated
for 12 h and phase contrast images were recorded in ten different
fields at the time of wounding (0 h) and 12 h thereafter. After
12 h, the migration of control and MUC4 knockdown cells was
measured. The results presented are the average of two independent experiments. Trans-well migration assays were performed as described previously [27] using a chamber with
monolayer-coated polyethylene terephthalate membranes (24-well
insert, pore size of 8 mm) for both control and MUC4 knockdown
cells. The results presented are the average of three experiments.

Cell Invasion Assay
The invasion assay was performed as described previously [28]
using a chamber with Matrigel-coated membrane inserts (24-well
insert, pore size of 8 mm) for both control and MUC4 knockdown
cells.

Immunofluorescence Staining and Confocal Laser
Scanning Microscopy

Microarray Gene Expression Analysis

Confocal analysis of control and MUC4 knockdown cells was
performed as described previously [25]. Briefly, cells were grown
onto 18 mm glass coverslips aseptically and fixed with 3.7%
paraformaldehyde and permeabilized with 0.5% Triton X-100.
Methanol (100%, ice chilled) was used for MUC4 staining. Next,
10% goat serum for 1 h in PBS was added to block nonspecific
binding sites. The primary antibody anti-MUC4 (1.86 mg/mL,
8G7; an antibody generated in our laboratory) was added to
coverslips at 1:200, and then incubated overnight at 4uC in 1%
goat serum in PBS. Alexa fluor-conjugated secondary antibody
(Jackson ImmunoResearch, West Grove, PA, USA) was added at
1:1000 in 1% goat serum in PBS for 1 h. DAPI staining was done
PLOS ONE | www.plosone.org

Total RNA was isolated using RNeasy Mini Kit columns as
described by the manufacturer (Qiagen, Valencia, CA, US). RNA
yield and purity were measured photo-metrically using nanodrop
(NanoDrop 1000 spectrophotometer, Thermo Scientific, Wilmington, Delaware USA) and also in criterion gel (Bio-Rad).
Spotted microarrays were used to identify differentially expressed
genes between MDA-MB-231-SCR (control) and MUC4 knockdown MDA-MB-231-shMUC4 samples. After reverse transcription with SuperScript II, cDNA was transcribed and control and
MUC4 knockdown samples were labeled with Cy3 and Cy5
respectively, and hybridized to HOA_005_0001 human OneAr3

February 2013 | Volume 8 | Issue 2 | e54455

Role of MUC4 in Triple Negative Breast Cancer

ray DNA microarrays (Phalanx Biotech, CA, USA) containing
30,275 features probing for approximately 22,000 unique genes,
according to standard procedures followed at the Microarray Core
Facility of the University of Nebraska Medical Center (UNMC),
Omaha, NE. A universal human reference (Stratagene, Cat:
740000, Cedar Creek, TX, US) was used for normalization.
Microarrays were scanned with the GenePix 4000B Scanner
(Axon Instruments, Foster City, CA, US). The Gene Expression
Omnibus (GEO) accession number for our micro array data is
GSE40157.
(http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token = nfqldmkagcqwcru&acc = GSE40157).

Results
MUC4 Promotes Proliferation and Growth
In a preliminary screening of breast cancer cells, we observed
that the invasive MDA-MB-231 TNBC cell line expressed MUC4
when grown in a-MEM media (Figure 1A, left lane), while noninvasive TNBC cell lines BT-20 and MDA-MB-468 [31] were
MUC4 negative (data not shown). Thus, we chose MDA-MB-231
cells for further studies and generated a line with stable knockdown
of MUC4 using a retroviral construct [7] to elucidate the
functional significance of MUC4 in TNBC pathophysiology. A
stable line generated with non-targeted scrambled shRNA (SCR)
was used as control for all experiments performed in this study.
Knockdown of MUC4 was confirmed by real-time PCR (data not
shown), immunoblotting, and immunofluorescence analyses
(Figure 1A). Immunoblot analysis indicated a ,95% downregulation of MUC4 at the protein level in MUC4 knockdown
cells (MDA-MB-231-shMUC4) as compared with control cells
(MDA-MB-231-SCR) cells.
Proliferation is an important cellular event in cancer cells.
Growth kinetic analysis showed that MUC4 knockdown cells had
a significantly lower (p = 0.03) proliferation rate with a doubling
time of 44 hours compared with control cells, which had a doubling
time of 32 hours (Figure 1B). Proliferation in cancer cells is mostly
driven by alterations in the cell cycle or apoptosis or both [32].
Therefore, we investigated the effect of MUC4 down-regulation
on cell cycle progression and apoptosis. Cell-cycle analyses
revealed that 57% of control cells were in the G1 phase, with
16% of cells in the G2/M phase (Figure 1C, please see Figure
S1A). In contrast, 67% of MUC4 knockdown cells were in G1,
with 12% in G2M (p = 0.005 and p = 0.037, respectively). Thus,
knockdown of MUC4 resulted in the accumulation of cells in the
G1 phase and inhibited their transition to G2/M via the S phase.
However, no significant change in apoptosis was observed
following MUC4 knockdown (Figure S1B). Under anchoragedependent conditions, MUC4 knockdown cells exhibited significantly lower (p = 0.003) colony-forming ability (56%) compared
with control cells (82%) (Figure 1D). When analyzed for
anchorage-independent growth in soft agar, control cells formed
numerous colonies (49569 per plate) after 2 weeks. In contrast,
MUC4 knockdown cells formed significantly fewer (9068 per
plate, p = 0.001) and smaller colonies, indicating that MUC4
expression contributes to a transformed phenotype of MDA-MB231 cells (Figure 1E).

Data Analysis and Real Time Validation
Data analysis and real time validation were performed using
standard procedure as described previously [23]. Briefly, array
quality control, statistical data analysis, and data visualization were
performed at the University of Nebraska Medical Center using
standard settings. Spot filters, background subtraction, and lowess
normalization were applied prior to data analysis through BRB
ArrayTools developed by Dr. Richard Simon and Amy Peng [29].
Genes were excluded if any of the spots were missing for any of the
samples. Random-variance paired t-tests were used to determine
those genes that were differentially expressed between control and
MUC4 knockdown samples, by comparing the log Cy3 (control)
and Cy5 (MUC4 knockdown) channel intensities. A significance
level of 0.001 was selected to limit the false discovery rate due to
multiple comparisons.
The microarray results were validated by RT-PCR. All RTPCR reactions were performed using SYBR green based
chemistry. For validation, eight of the differentially expressed
genes, 4 up-regulated (COL4A5, SMAD6, CXCL1, and DUSP2)
and 4 down-regulated (A100A4, PDGFRB, SOCS2, and
PLCXD1), detected by microarray were selected. Validation was
done using randomly selected original samples (submitted for
microarray analysis) and in freshly isolated RNA from both control
and MUC4 knockdown cells. Relative gene expression was
determined using the 2-ddCT method. Primers were custom
synthesized from IDT technology and are listed in Table S2.

In vivo Tumorigenesis and Metastasis in Nude Mice
To test tumorigenicity and metastasis, control and MUC4
knockdown cells (0.1 6 106) were orthotopically injected into the
mammary fat pads of nude female mice (The Jackson Laboratory,
Bar Harbor, ME, USA; and n = 9 for each group) and the growth
of tumors was followed for 8 weeks using procedures described
previously [30]. After 8 weeks, mice were euthanized according to
IACUC (Institutional Animal Care and Use Committee) guidelines and checked for tumor size and metastasis. To confirm
reduced metastasis by MUC4 knockdown cells, 0.3 6 106 cells
were orthotopically injected into the mammary fat pads of nude
female mice (n = 6). After 8 weeks, animals were euthanized as
above and checked for tumor size and metastasis. The results
presented are the average of two independent experiments.
Institutional Animal Care and Use Committee at University of
Nebraska Medical Center has approved to proceed the above
mentioned experiments. The approval number is 12-031-FC.

MUC4 Up-regulates the EGFR Family of Proteins and
Induces Downstream Signaling
EGFR plays important roles in the proliferation of TNBC [33],
while MUC4 has been demonstrated to stabilize another EGFR
family member, ErbB2 [25]. Thus, we studied the effect of MUC4
knockdown on the status of EGFR family members and
downstream signaling. Knockdown of MUC4 resulted in reduced
expression of ErbB1 (EGFR) and ErbB3, whereas ErbB4 levels
remained unchanged (Figure 2A). This result suggests that
MUC4 may use an alternative mechanism to promote aggressiveness and metastasis of TNBC cells, because ErbB2 was present at
low levels in TNBC cells. Sprouty 2 enhances EGFR stability by
sequestering Cbl (Casitas B-lineage Lymphoma-an E3 ubiquitin
ligase), and thus inhibiting ubiquitin-mediated degradation of
EGFR [34]. We observed a decreased expression of Sprouty 2 in
MUC4 knockdown cells compared with control cells (Figure 2B).
Alteration of EGFR expression by MUC4 resulted in enhanced
downstream signaling via Erk1/2 and PKC-c pathways, as
indicated by increased phosphorylation of Erk1/2 and increased

Statistical Analysis
Data were analyzed using two-tailed Student’s t-tests and twotailed Fisher’s exact tests where appropriate in Microsoft Excel
2010. The software used for the Wilcoxon rank sum test is SAS
software (SAS Institute Inc., Cary, NC). P,0.05 was considered
statistically significant.
PLOS ONE | www.plosone.org
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Figure 1. MUC4 promotes proliferation and growth of MDA-MB-231 cells. (A) Detection of MUC4 protein expression in control (MDA-MB231-SCR) and MUC4 knockdown (MDA-MB-231-shMUC4) cells. Immunoblot showed reduced expression of MUC4 in MDA-MB-231-shMUC4 cells
compared to control cells. Immunostained cells using human anti-MUC4 mouse monoclonal antibody (8G7) showed reduced expression of MUC4 in
MDA-MB-231-shMUC4 cells compared to control cells. (B) In proliferation analyses, when the number of cells was plotted against the incubation
period (hours), control cells showed a significantly higher proliferation rate than MUC4 knockdown cells, p = 0.03. Population doubling time of control
cells was less than MUC4 knockdown cells when calculated from the number of cells growing in log phase (day 2 to 6) using the formula, Td = 0.693t/
ln (Nt/N0). (C) Cells, following synchronization and serum re-stimulation and stained with Telford reagent (containing propidium iodide) and analyzed
by FACS, showed that the number of MUC4 knockdown cells in the G1 phase was higher than control cells suggesting the inhibition of cell cycle
progression. (D) The colony forming ability of control cells was higher than MUC4 knockdown cells under anchorage-dependent conditions. After
staining, colonies of .50 mm in size were counted using Quantity One software, p = 0.003. Images of anchorage–dependent growth assays were
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shown at the bottom. (E) The colony forming ability of control cells was higher than MUC4 knockdown cells under anchorage-independent
conditions. Colonies were counted and plotted. Columns: mean of triplicates; bars: SD, p = 0.0001. Phase-contrast images were recorded at 106
magnification. Microscopic images of colonies found in anchorage–independent growth assays. Higher magnification of a typical colony was shown
in box on bottom right corner to emphasize a (i) big colony with migratory outer cells versus (ii) smaller and compact colonies. SCR are control and
shMUC4 are MUC4 knockdown cells. All data presented are the average of 3 independent experiments.
doi:10.1371/journal.pone.0054455.g001

expression of PKC-c in control cells (Figure 2C). Furthermore,
MUC4 knockdown resulted in decreased expression of cyclin D1
and its upstream regulator b-catenin, suggesting that MUC4
augments cell cycle progression possibly via cyclin D1(Figure 2D).

MUC4 Enhances Migratory and Invasive Potential
In addition to enhanced proliferation, the aggressiveness of
a malignant cell is determined by its migratory and invasive
potential. MUC4 knockdown cells exhibited significant decrease in
motility, trans-well migration, and invasion (p = 0.01, p = 0.002,
and p = 0.001, respectively). The motility of cells, determined by
their migration in the wound gap after 12 h, in the wound healing
assay decreased by 18% following MUC4 knockdown (Figure 3A).
Similarly, trans-well migration and Matrigel invasion (Figure 3BC) of MUC4 knockdown cells was decreased by 58% and 65%,
respectively. Since actin plays an important role in defining cell
shape and orchestrating events related to cellular motility, we
investigated the effect of MUC4 on actin cytoskeleton reorganization. Following cell staining with rhodamine-conjugated phalloidin, control cells exhibited more lamellipodial structures
compared to MUC4 knockdown cells, which had reduced F-actin
(Figure 3D) and decreased levels of phosphorylated (Y925) focal
adhesion kinase (Figure 3E). These results strongly suggest that
MUC4 facilitates the migratory and invasive potential of MDAMB-231 cells by inducing the reorganization of actin filaments.
Since alterations in cell motility and cytoskeleton reorganization
are associated with epithelial-to-mesenchymal transition (EMT),
we investigated whether MUC4 regulates EMT in MDA-MB-231
cells. MUC4 Knockdown resulted in increased expression of the
epithelial marker CK-18, and decreased expression of mesenchymal markers vimentin and vitronectin (Figure 3F).

MUC4 Contributes to an Altered Morphology of Colonies
Epithelial cells in the mammary gland maintain a polarized
morphology, specialized cell-cell contacts, and attachment to the
underlying basement membrane. The development and maintenance of this polarized structure are critical for the formation and
function of mammary epithelial cells [35]. However, the pathogenesis of tumors originating from epithelial cells requires the
disruption of this intact and well-organized structural design. We
used a 3D Matrigel culture model [36] to determine the effect of
MUC4 knockdown on the morphology of the resulting 3D
structures. The control cells failed to polarize in Matrigel and
formed large, disorganized colonies. MUC4 knockdown did not
induce structural polarization, but resulted in the formation of
more organized structures reminiscent of mammary gland acini
(Figure 4A). Confocal imaging of 3D Matrigel structures for ZO1, a tight junction protein, further confirmed that control cells
predominantly form disorganized and larger 3D colonies in
Matrigel (83%) compared with the MUC4 knockdown cells (23%;
p = 0.002) (Figure 4B). These results indicate that MUC4 induces
the transformation of MDA-MB-231 cells to a highly migratory
phenotype, and that stable MUC4 knockdown partially reduces
this phenomenon.

Figure 2. MUC4 up-regulates EGFR family receptors and
induces downstream Erk1/2 and PKC-c pathways. (A) Immunoblot analyses showed reduced expression of EGFR, ErbB2, and ErbB3 in
MUC4 knockdown cells compared with control cells. (B) Reduced
expression (using immunoblot) of Sprouty 2 was detected in MUC4
knockdown cell when compared with control cells. (C) Immunoblot
showed that reduced phosphorylation of Erk1/2 and expression of PKCc in MUC4 knockdown cells compared with control cells. b-actin was
used as a loading control. (D) Immunoblot analyses showed reduced
expression of b-catenin and its target gene product cyclin D1in MUC4
knockdown compared with control cells.
doi:10.1371/journal.pone.0054455.g002
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MUC4 Promotes Tumorigenesis and Metastasis
As MUC4 knockdown was observed to augment proliferation,
growth, migration, and invasion of MDA-MB-231 cells, we sought
to investigate the effect of MUC4 knockdown on the tumorigenic
and metastatic potential of MDA-MB-231 cells. Control and
MUC4 knockdown cells were implanted orthotopically into
mammary fat pads of two groups of female nude mice (n = 9).
6
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Figure 3. MUC4 enhances migratory and invasive potential. (A) After 24 hours serum starvation, a wound was created with a plastic tip on
plates containing control or MUC4 knockdown cells. Cells were incubated in complete media for 12 hours. Motility of cells was photographed under
bright-field microscopy (left, 106 magnification). After 12 hours, the migration of control cells and MUC4 knockdown cells was measured (in mm2)
using DatInf Measure setup wizard software (http://tucows.texasonline.net). Values were calculated and plotted (right). (B and C) Control and MUC4
knockdown cells were serum starved for 48 h and seeded on non-coated or Matrigel-coated membranes for motility (B) and invasion (C) assays,
respectively, and incubated for 24 h. Medium containing 10% fetal bovine serum in the lower chamber was used as a chemo-attractant. Cells that did
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not migrate through the Matrigel and/or pores in the membrane were removed using a cotton swab, and cells on the other side of the membrane
were stained and photographed under bright-field microscopy (106 magnification). The number of cells that migrated and invaded was higher in
control than the MUC4 knockdown cells. Data presented are the average number of cells/field for 10 fields. Columns: average of three independent
experiments; bars: SE, p = 0.002 and p = 0.001, respectively. Representative images of control and MUC4 knockdown cells were shon in both figures.
(D) Phalloidin staining showed that visualized F-actin under a laser scanning microscope is reduced in MDA-MB-231-shMUC4 cells compared with the
control cells. (E) Immunoblot analysis showed reduced phosphorylation of FAK in MUC4 knockdown cells compared with the control cells. (F)
Immunoblot analysis showed reduced expression of mesenchymal markers such as vimentin and vitronectin; and increased expression of CK-18 in
MUC4 knockdown cells compared to the control.
doi:10.1371/journal.pone.0054455.g003

knockdown vs. 0.65360.07 g in control cells) (Figure 5B). In
addition, in vivo transgene expression in control cells was
confirmed in excised tumors at the mRNA and protein levels
(Figure S2A-B). Next, we determined the frequency of metastases
in mice implanted with control or MUC4 knockdown cells. All
mice, implanted with control cells, developed metastases to one or

Control cells produced detectable tumors at week 3, while tumors
resulting from MUC4 knockdown cells were detectable only after
5 weeks (Figure 5A). The tumor volume from MUC4 knockdown
cells was significantly smaller (p = 0.0001) and the tumors excised
at 8 weeks had markedly reduced weight, compared with tumors
obtained from control cells (mean 0.17160.05 g in MUC4

Figure 4. MUC4 contributes to a altered phenotype. (A) The control or MUC4 knockdown cells were seeded in 2% Matrigel on top of a 100%
Matrigel layer, and fed with media every 3 days. After 7 days, acini-like structures were photographed under a phase-contrast microscope. The acinilike structures (examples shown in the boxes) that were regular (smooth and spherical shape) or irregular (irregular outline, multi-lobular) were
counted and plotted as a percentage of the total count (p = 0.0005 for regular and p = 0.002 for irregular). A minimum of 120 structures was counted
for each of control cells or MUC4 knockdown cells. Reduced irregular outline, multi-lobular and increased smooth and spherical shape colonies were
found in MUC4 knock down cells when compared with control cells. (B) Structures were stained with the anti-ZO-1 antibody. 4,6-diamidino-2phenylindole (DAPI) was used for nuclei staining. Optical sections (0.7–0.9 mm) were captured using a laser scanning confocal microscope. The
images presented here are the central planes of the acini. Bar = 20 mm.
doi:10.1371/journal.pone.0054455.g004
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multiple sites. Metastasis was observed in 2 of nine mice of each
organ such as lung, ovary, and peritoneum and; in 3 of nine of
each site like mesenteric lymph nodes, and intestinal wall. In
contrast no metastasis was observed in mice implanted with
MUC4 knockdown cells. In an independent experiment, larger
tumors were obtained by orthotopically implanting 36 more
MUC4 knockdown cells (0.3 6106). However, these tumors, while
comparable in size to the previously obtained control tumors
(0.75 g), were still incapable of distant metastasis, suggesting that
the differences in the metastatic potential of control and MUC4
knockdown cells is independent of the size of the primary tumor
(Table S1).

Triple Negative Breast Cancer Tissues Overexpress MUC4
Mucin
To determine the clinical relevance of MUC4 expression in
TNBCs, immunohistological analyses were performed on TNBC
tumor microarrays using anti-MUC4 antibody [37]. While
expression of MUC4 was not detected in normal breast tissues,
primary invasive TNBC tissues were found to be positive for
MUC4 expression (Figure 6). A total of 35 primary tissues, and 6
normal breast tissues were examined. No expression of MUC4 was
observed in the normal breast tissues (0/6, composite score 060),
however, 54% (20/35, composite score 2.761.3, p = 0.018)
primary invasive TNBC tissues were found to be positive for
MUC4 expression. Composite score calculated based on only 20
MUC4 positive samples was 4.862.7, p = 0.0002.

MUC4-associated Gene Expression, Pathways, and
Interaction Networks
We investigated alterations at transcript level following MUC4
knockdown in MDA-MB-231 cells using human genome microarray analysis. A total of 175 genes exhibited a .2 fold differential
expression in MUC4 knockdown cells compared with control cells.
The top-scoring network of interactions among the differentially
expressed genes in control versus MUC4 knockdown cells is shown
along with the table that lists statistically significant enriched highlevel functions (Figure S3). In agreement with the results
presented in Figure 2C, the Erk1/2 and MAPK nodes were
highly perturbed upon MUC4 silencing (Figure S3). Selected
genes that exhibited the most differential expression in MUC4
knockdown cells are listed in Figure S4A-C. Analyses of the data
revealed that several genes associated with cellular motility,
proliferation, inflammatory response, and cellular signaling, were
differentially regulated in MUC4 knockdown cells. Some important genes COL4A5, SMAD6, CXCL1, and DUSP2 were found to be
up-regulated and several other genes A100A4, PDGFRB, CAV1,
and CAV2 were found to be down-regulated and hence were
validated (Figure 7). The results of the real time analyses were in
complete agreement with the microarray data, indicating that
these genes could be involved in mediating the modulation of
signaling pathways by MUC4.

Figure 5. MUC4 promotes growth of MDA-MB-231 xenografts.
(A) MUC4 knockdown and control cells (0.1 6 106 cells/animal) were
orthotopically implanted in mouse mammary fat pad of each mouse
(right 3rd mammary gland). Tumor volumes were calculated every week.
The MUC4 knockdown cells started to grow tumors during the 5th
week, but control cells started to grow tumors during the 3rd week,
p = 0.0001. (B) Eight weeks after implantation, mice were sacrificed and
tumors were excised and weighed. Stable silencing of MUC4 was found
to decrease tumor growth, p = 0.0001.
doi:10.1371/journal.pone.0054455.g005

Discussion
Although there is a high incidence of MUC4 expression in
breast cancer [15] and a significant association with metastatic
disease [16], limited information is available regarding its
functional role(s) in breast cancer especially in the triple negative
sub-type. We have demonstrated previously that the MUC4
promotes cell proliferation and survival by binding to the receptor
tyrosine kinase ErbB2 and activating downstream signaling
[10,25]. This present study represents the first effort to define
PLOS ONE | www.plosone.org

the functional roles of human MUC4, specifically in invasive
TNBC cells.
Knockdown of MUC4 in MDA-MB-231 cells resulted in
a reduced growth rate, indicating that MUC4 augments cell
proliferation. Previous studies from our laboratory have indicated
that MUC4 augments proliferation and motility of pancreatic and
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Figure 6. Differential over-expression of MUC4 mucin in TNBC tissues compared with normal breast tissues. Immunohistological
analyses were performed using the anti-MUC4 mouse monoclonal antibody (2214, generated in our laboratory, against a sequence close to the Nterminus of human MUC4) on tumor microarrays (BR1503 and BR10010) containing normal breast and invasive TNBC tissues and observed under
a Nikon light microscope. MUC4 expression in invasive primary (n = 35) TNBC tissues were compared with normal breast tissue (n = 6) in a set of
arrays. High immune-reactivity for MUC4 was detected in invasive TNBC tissues, but not in normal breast tissues. The image presented was taken at
46 magnification, and the higher magnification images (marked with a red box) were taken at 106 magnification.
doi:10.1371/journal.pone.0054455.g006

ovarian cancer cells [7,10,12,38]. In cancer cells, proliferation is
mostly driven by altered cell cycle progression [32]. Increased
accumulation of MUC4 knockdown cells in the G0-G1 phase
suggests that MUC4-dependent signaling mediates cell cycle
progression in MDA-MB-231 cells. Thus, we have shown that
MUC4 augments proliferation by regulating cell cycle progression
without altering apoptosis. Further investigation revealed that
enhanced cell cycle progression is partly mediated by sustained
expression of b-catenin, and thereby increased expression of cyclin
D1 in control cells. MUC4 augmentation of cell cycle progression
is also supported by our earlier findings in pancreatic cancer cells
[7].
Among four members of the ErbB family, EGFR and ErbB2
play major roles in different types of breast cancer [39–43]. The
majority of TNBCs over-express EGFR [44,45], and are therefore
candidates for anti-EGFR therapies [46]. Our earlier studies
demonstrated that MUC4 regulates ErbB2 expression by enhancing its stability without affecting its transcription or mRNA
stability [25]. Unlike EGFR, ErbB2 is present at low levels in
TNBC cells. Here, for the first time, we showed that MUC4
regulates the expression of all EGFR family receptors excluding
ErbB4. This result suggests that MUC4 is using an alternative
mechanism to promote the aggressiveness of TNBC cells.
However, the effect of MUC4 on the levels of other receptor
tyrosine kinases needs further research. Sprouty 2 attenuates
EGFR ubiquitination and endocytosis, and therefore enhances
Ras/ERK signaling [47]. We observed that MUC4 mucin
PLOS ONE | www.plosone.org

increased Sprouty 2 expression, and thereby potentially prevents
the ubiquitin-mediated degradation of EGFR. The increased level
of EGFR in MDA-MB-231 cells potentiates growth promoting
downstream signaling cascades, as evident from phosphorylation
of ERK1/2 and up-regulation of PKC-c. Further evidence of the
enhanced oncogenic potential of MUC4 expressing cells was
shown by their ability to undergo anchorage-dependent and independent growth, a trait commonly used to determine the
oncogenicity of cells in vitro [48]. Obvious increases in soft agar
large colony formation were observed in control compared with
MUC4 knockdown cells. Large colony formation in soft agar was
inhibited by MUC4 knockdown, indicative of MUC4 dependence.
Overall, analyses of soft agar colony formation together with
functional indicators of oncogenesis show that MUC4 promotes
oncogenic phenotypes of MDA-MB-231 cells.
Motility and invasion are also major events in the metastasis of
cancer [49,50], and are associated with poor prognosis in patients
with cancer. Additionally, the migratory and invasive potential of
cells are typically associated with the reorganization of actin and
thereby formation of lamellipodia [51]. However, the mechanisms
associated with cell invasiveness remain poorly understood. Here,
we demonstrate that MUC4 promotes the migratory and invasive
potential of TNBC cells (Figure 3). Knockdown of MUC4 in
MDA-MB-231 cells reduced migratory and invasive behaviors
in vitro by cytoskeletal rearrangement, specifically by suppressing
F-actin formation. Noticeably, MUC4 knockdown cells exhibited
smaller pseudopodial projections, while control cells showed long
10
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secondary sites [49]. Our results indicate that MUC4 may
potentiate the metastatic behavior of TNBC cells by inducing
cytoskeletal rearrangement. The decreased proliferation rate,
motility, and invasive potential observed in vitro following MUC4
knockdown resulted in reduced tumorigenicity and metastatic
potential in vivo, when control and MUC4 knockdown cells were
orthotopically implanted in mice. This strongly indicates that
MUC4 is associated with the oncogenicity of MDA-MB-231 cells.
Our experimental findings are in agreement with the expression
profile of MUC4 in a small set of clinical TNBC samples. We
observed that MUC4 is over-expressed in invasive TNBC tissues,
but not expressed in normal breast tissues. These preliminary
studies provide a strong rationale to undertake a future study in
a larger sample set to determine the association of MUC4 with
TNBC and other breast cancer sub-types. Taken together these
findings suggest an important role for MUC4 in tumorigenesis and
metastasis of TNBCs.
To further understand MUC4-mediated oncogenic signaling
pathways, we studied global alterations in gene expression.
Detailed analyses of microarray data further support the concept
that MUC4 confers oncogenic potential to MDA-MB-231 cells.
The top-scoring network of interactions (Figure S3) among the
differentially expressed genes in control versus MUC4 knockdown
cells involved Erk1/2, which is in complete agreement with the
reduced levels of phosphorylated Erk1/2 observed in the
immunoblotting experiments (Figure 2C). Moreover, we observed statistically significant changes in high-level cellular
functions (Figure S3) including metastasis (22 genes), apoptosis
(15 genes), tumorigenesis (12 genes), cell movement (17 genes),
proliferation (29 genes), disassembly of focal adhesions (6 genes),
and disassembly of actin filaments (7 genes). In addition,
knockdown of MUC4 up-regulated membrane components such
as type IV collagen (COL4A5), an antagonist of signaling by TGFb type 1 receptor super family members (SMAD6). Knockdown of
MUC4 also up-regulated DUSP2, a dual phosphatase kinase, and
thereby down-regulated mitogenic signal transduction by dephosphorylating both Thr and Tyr residues on Erk1/2, and agrees
well with our immunoblotting data (Figure 2C). Furthermore,
MUC4 knockdown up-regulated CXCL1, which is a ligand of
CXCR1 and CXCR2. Controlling the levels of cytokines including CXCL1 is important for controlling immune cell
infiltration, and ultimately in vivo tumor growth [58]. The effects
of increased CXCL in the current study warrant further research.
The expression of S100A4, PDGFR, CAV1, CAV2, and many
other genes was down-regulated in MUC4 knockdown cells. The
S100A4 protein functions in motility, invasion, and tubulin
polymerization of many cell types [59]. Chromosomal abnormalities and altered expression of S100A4 have been implicated in
tumor metastasis [60]. The binding of ligands (PDGF-a, -b, -c,
and –d) activates the intracellular kinase activity of PDGFR, and
initiates intracellular signaling through the MAPK, PI3-K, and
PKC-c pathways. The down-regulation of PKC-c upon MUC4
knockdown is in agreement with our western blot data
(Figure 2C). Caveolin expression is elevated in breast cancer
and associated with both primary and metastatic breast cancer
[61]. CAV1 (caveolin-1), has been identified as a marker
associated with a basal-like phenotype in both hereditary and
sporadic breast cancer [62], and has been proposed to play a role
in intracellular cholesterol trafficking [63]. A schematic of the
overall study performed indicates several pathways of involvement
of MUC4 in the pathogenesis of invasive TNBCs (Figure 8).
Altogether, these results suggest that MUC4 modulates multiple
signaling pathways that confer aggressiveness to MDA-MB-231
cells.

Figure 7. MUC4-associated gene expression, pathways, and
interaction networks in MDA-MB-231 cells. Array data were
validated using RT-PCR using specific primers: 20 ng mRNA from
control and MUC4 knockdown cells were reverse transcribed and used
for RT-PCR using MUC4 specific primers and the LightCycler SYBR Green
1 Master. The b-actin specific primers were used as control. CT values
were calculated and plotted to verify the up-regulated and downregulated genes.
doi:10.1371/journal.pone.0054455.g007

pseudopodial projections. The rearrangement of F-actin is
associated with EMT and, therefore, increases motility [52].
Here, we showed decreased F-actin formation along with reduced
motility in MUC4 knockdown cells. Furthermore, elevated
expression of focal adhesions kinase (FAK) in human breast
tumors has been correlated with increased malignancy and
invasiveness [53]. MUC4 knockdown cells also had reduced
phosphorylation of FAK, which possibly contributed to reduced
motility of these cells. b-catenin, through its re-localization from
membrane cadherin complexes to the nucleus, can act as a cotranscription factor and signaling molecule, and induces epithelial
cell migration [54]. We observed decreased b-catenin expression
in MUC4 knockdown cells, which further explains reduced
motility and EMT in these cells. EMT promotes dissemination
of a single carcinoma cell from the sites of primary tumors to
distant organs (metastasis). In addition, EMT is required for
normal mammary gland development [55] and plays a major role
in breast cancer progression [56]. We observed that MUC4
knockdown resulted in increased expression of epithelial markers
and decreased levels of mesenchymal markers, suggesting that
MUC4 knockdown switches MDA-MB-231 cells to an epithelial
from a mesenchymal phenotype. This observation is in agreement
with our recent findings that showed the involvement of MUC4 in
EMT in ovarian cancer cells [57]. Analyses of oncogenic behavior
using biologically relevant and sensitive 3D Matrigel cultures
showed that MUC4 expression in MDA-MB-231 contributes to
their oncogenic potential. Although MUC4 knockdown did not
induce structural polarization, organized structures reminiscent of
mammary gland acini did appear. The process of metastasis is
a complex phenomenon regulated by many components that
facilitate the detachment of tumor cells from primary tumors to
PLOS ONE | www.plosone.org
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Figure 8. A schematic diagram showing the contribution of MUC4 in the overall aggressiveness of TNBC cells. MUC4 maintains the
sustained expression of EGFR family proteins and thereby potentiates downstream signaling events mediated through the PKC-c and Erk1/2
signaling. MUC4 maintains sustained expression of b-catenin, which induces proliferation, tumorigenesis, migration, invasion, and metastasis.
doi:10.1371/journal.pone.0054455.g008

CT values were calculated and plotted. (B) Immunoblot analysis of
tumor samples. A total of 50 mg of protein from tumors was
immunoblotted using 8G7 anti-MUC4 monoclonal antibody.
(TIF)

Conclusions
In conclusion, we have shown for the first time that MUC4
promotes TNBC cell invasive activity through EGFR family
protein (EGFR, ErbB2 and ErbB3) and its downstream signaling
(Figure 8). We have also shown that MUC4 is differentially overexpressed in primary and metastatic TNBC tissues compared with
normal breast tissues. Therefore, MUC4 could be a new potential
target for the treatment of invasive TNBCs.

Figure S3 The top-scoring network of interactions

among the differentially expressed genes in control
versus MUC4 knockdown cells. The table lists statistically
significant enriched high-level cellular functions.
(TIF)

Supporting Information

Figure S4 Regulated mRNAs in MDA-MB-231 cells,

(A) Histograms of cell cycle analyses of
control and MUC4 knockdown cells. (B) Histograms of
apoptosis assays of control and MUC4 knockdown cells.
(TIF)

Figure S1

after knockdown of MUC4, using human genome array
analysis. (A) BRB-Arraytools hierarchical clustering of genes
with large fold-change. (B) Names and average log fold-change
values of selected down-regulated genes. (C) Names and average
log fold-change values of selected up-regulated genes. (*) real-time
PCR validated genes.
(TIF)

Figure S2 MUC4 down-regulation maintained in a tu-

mor generated by the orthotopic implantation of MDAMB-231-shMUC4 cells in mammary fat pads of nude
mice. (A) Real-time PCR analysis of tumor samples. A total of
20 ng mRNA from tumors was reverse transcribed and used for
real-time-PCR using MUC4 specific primers and SYBR green
master mix. The GAPDH specific primers were used as control.
PLOS ONE | www.plosone.org

Metastatic spread in nude mice when MUC4
knockdown (MDA-MB-231-shMUC4) cells were implanted (0.36106 cells) into the right 3rd mammary fat
Table S1
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